Rake, Bastian (2022) Waiving intellectual property rights: Boom or bust for medical innovation? Drug Discovery Today, 27 (2). pp. 384-389. ISSN 1359-6446

Preview

Download (198kB) | Preview

Abstract

Proposals to waive intellectual property rights (IPRs) on coronavirus 2019 (COVID-19)-related developments have gained considerable support among politicians, including from US President Biden, academics, nongovernmental organizations (NGOs), the media, and the general public. However, there are surprisingly few reflections about the short- and long-term consequences for medical innovation, particularly the development of new drugs and vaccines. In this feature, I reflect on the consequences for innovative entrepreneurial companies, the incentives to innovate, and consequences for international knowledge flows to low- and middle-income countries. I conclude that waiving IPRs reduces opportunities for entrepreneurial companies to attract sufficient funding for developing medical innovations. Low- and middle-income countries might suffer reduced knowledge inflows in the absence of IPRs that undermine their ability to develop medical innovations.

Item Type:	Article
Keywords:	COVID-19 vaccines; Incentivizing innovation; Intellectual property rights; Knowledge transfer; Low- and middle-income country; Patent waiver;
Academic Unit:	Faculty of Social Sciences > School of Business
Item ID:	18249
Identification Number:	https://doi.org/10.1016/j.drudis.2021.10.015
Depositing User:	Bastian Rake
Date Deposited:	06 Mar 2024 15:42
Journal or Publication Title:	Drug Discovery Today
Publisher:	Elsevier
Refereed:	Yes
URI:	Publisher
Use Licence:	This item is available under a Creative Commons Attribution Non Commercial Share Alike Licence (CC BY-NC-SA). Details of this licence are available here

Repository Staff Only(login required)

Item control page

Downloads

Origin of downloads